@article{a0faea911b4f4b03b3e830ad32fc6f4d,
title = "Monitoring Progressive Multiple Sclerosis with Novel Imaging Techniques",
abstract = "Imaging markers for monitoring disease progression in progressive multiple sclerosis (PMS) are scarce, thereby limiting the possibility to monitor disease evolution and to test effective treatments in clinical trials. Advanced imaging techniques that have the advantage of metrics with increased sensitivity to short-term tissue changes and increased specificity to the structural abnormalities characteristic of PMS have recently been applied in clinical trials of PMS. In this review, we (1) provide an overview of the pathological features of PMS, (2) summarize the findings of research and clinical trials conducted in PMS which have applied conventional and advanced magnetic resonance imaging techniques and (3) discuss recent advancements and future perspectives in monitoring PMS with imaging techniques.",
keywords = "Advanced imaging, Biomarker, Clinical trials, Progressive multiple sclerosis",
author = "Maria Petracca and Monica Margoni and Giulia Bommarito and Matilde Inglese",
note = "Funding Information: No funding or sponsorship was received for this study or publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Maria Petracca, Monica Margoni and Giulia Bommarito declare that they have nothing to disclose. Matilde Inglese has received research grants from Novartis Pharmaceuticals, the National Multiple Sclerosis Society, the Noto Foundation, NIH and TEVA Neuroscience. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Funding Information: Disclosures. Maria Petracca, Monica Mar-goni and Giulia Bommarito declare that they have nothing to disclose. Matilde Inglese has received research grants from Novartis Pharmaceuticals, the National Multiple Sclerosis Society, the Noto Foundation, NIH and TEVA Neuroscience. Publisher Copyright: {\textcopyright} 2018, The Author(s).",
year = "2018",
month = dec,
day = "1",
doi = "10.1007/s40120-018-0103-2",
language = "English",
volume = "7",
pages = "265--285",
journal = "Neurology and Therapy",
issn = "2193-8253",
publisher = "Springer Healthcare",
number = "2",
}